ZyVersa Therapeutics Book Value Per Share vs. Short Ratio
| ZVSA Stock | 1.30 0.10 7.14% |
Book Value Per Share | First Reported 2010-12-31 | Previous Quarter 113.58212568 | Current Value 90.74 | Quarterly Volatility 108.69529422 |
For ZyVersa Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ZyVersa Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ZyVersa Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ZyVersa Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ZyVersa Therapeutics over time as well as its relative position and ranking within its peers.
ZyVersa |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.2 K | Return On Assets (0.25) | Return On Equity (1.52) |
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ZyVersa Therapeutics Short Ratio vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ZyVersa Therapeutics's current stock value. Our valuation model uses many indicators to compare ZyVersa Therapeutics value to that of its competitors to determine the firm's financial worth. ZyVersa Therapeutics is rated second in book value per share category among its peers. It is rated fourth in short ratio category among its peers fabricating about 0.02 of Short Ratio per Book Value Per Share. The ratio of Book Value Per Share to Short Ratio for ZyVersa Therapeutics is roughly 57.36 . At present, ZyVersa Therapeutics' Book Value Per Share is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ZyVersa Therapeutics' earnings, one of the primary drivers of an investment's value.ZyVersa Short Ratio vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
ZyVersa Therapeutics |
| = | 10.32 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
ZyVersa Therapeutics |
| = | 0.18 X |
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
ZyVersa Short Ratio Comparison
ZyVersa Therapeutics is currently under evaluation in short ratio category among its peers.
ZyVersa Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ZyVersa Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ZyVersa Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of ZyVersa Therapeutics' change in net profit over the period of time. It can combine multiple indicators of ZyVersa Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -1.1 K | -1.2 K | |
| Net Interest Income | -49.2 K | -51.6 K | |
| Operating Income | -14.4 M | -15.1 M | |
| Net Loss | -89.6 M | -85.1 M | |
| Income Before Tax | -107.8 M | -102.4 M | |
| Total Other Income Expense Net | -93.3 M | -88.7 M | |
| Net Loss | -12.7 M | -13.3 M | |
| Net Loss | -98.3 M | -93.4 M | |
| Income Tax Expense | -9.5 M | -9 M | |
| Interest Income | 411.30 | 365.60 | |
| Change To Netincome | 3.2 M | 3 M | |
| Net Loss | -1 K | -1.1 K | |
| Income Quality | 0.09 | 0.08 | |
| Net Income Per E B T | 0.91 | 0.87 |
ZyVersa Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ZyVersa Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ZyVersa Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ZyVersa Therapeutics' important profitability drivers and their relationship over time.
Use ZyVersa Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ZyVersa Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ZyVersa Therapeutics will appreciate offsetting losses from the drop in the long position's value.ZyVersa Therapeutics Pair Trading
ZyVersa Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to ZyVersa Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ZyVersa Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ZyVersa Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ZyVersa Therapeutics to buy it.
The correlation of ZyVersa Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ZyVersa Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ZyVersa Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ZyVersa Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ZyVersa Therapeutics position
In addition to having ZyVersa Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate Bonds Funds Thematic Idea Now
Corporate Bonds Funds
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Current Watchlist. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
To fully project ZyVersa Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ZyVersa Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ZyVersa Therapeutics' income statement, its balance sheet, and the statement of cash flows.